Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery

Qian Ding, Zugui Zhang, Hong Liu, Huang Nie, Mark Berguson, Jordan E. Goldhammer, Nilas Young, Douglas Boyd, Rohinton Morris, Jianzhong Sun

Thumb 65bb0659497b85bae0759dc2a6b4b5db 400x400
Aug 15, 2018

Received: 25th July 18

This study examined association between use of perioperative renin-angiotensin system inhibitors (RASi) and outcomes in patients undergoing coronary artery bypass graft (CABG) and/or valve surgery. Of all the patients, 8,112 patients met inclusion criteria and were divided into four groups: with or without preoperative (PreRASi) or postoperative RASi (PostRASi) respectively. With the use of propensity scores matching and sensitivity analyses to reduce treatment selection bias, this cohort study showed that PreRASi was associated with a significant reduction in postoperative 30-day mortality compared with without one (3.41% vs. 5.02%, OR 0.69, 95% CI 0.54 – 0.90, P=0.01); PostRASi was associated with reduced long-term mortality rate compared with without one (3.66% vs. 4.86%, RR 0.75, 95% CI 0.57 – 0.93 at 1 year; 17.12% vs. 19.91%, RR 0.86, 95% CI 0.75 – 0.97 at 6 year; P= 0.0250 respectively). The results suggest that perioperative use of RASi has a significant benefit for the postoperative and long-term survival among patients undergoing cardiac surgery.

Read in full at OSF PREPRINTS.

This is an abstract of a preprint hosted on an independent third party site. It has not been peer reviewed but is currently under consideration at Nature Communications.

Medium 65bb0659497b85bae0759dc2a6b4b5db 400x400

Nature Communications

Nature Research, Springer Nature